<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01215838</url>
  </required_header>
  <id_info>
    <org_study_id>DI-2009-1</org_study_id>
    <secondary_id>7160</secondary_id>
    <nct_id>NCT01215838</nct_id>
  </id_info>
  <brief_title>MRI of the Liver With Eovist</brief_title>
  <official_title>Dynamic Contrast Evaluation of the Liver Using Gadoxetate Disodium (EovistÂ®) for Hepatocellular Carcinoma (HCC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if a new magnetic resonance (MR) protocol is better
      at diagnosing liver lesions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hepatocellular carcinoma (HCC), a form of liver cancer, is the seventh most common cause of
      cancer mortality in the US. The incidence rate of HCC is increasing along with the incidence
      of Hepatitis B and C which are known to promote HCC. Patients have a better prognosis
      (survival outlook) if HCC is found and treated at an early stage. MRI is the best imaging
      modality for diagnosing HCC.

      This study will compare standard MRIs and MRIs performed with a newly developed MR protocol
      to determine if it is possible to more confidently diagnose HCC.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Unable to meet enrollment expectations.
  </why_stopped>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Accuracy of a new MR protocol in diagnosing HCC and other liver lesions.</measure>
    <time_frame>One day: participants will have one MRI of the liver.</time_frame>
  </primary_outcome>
  <enrollment type="Actual">4</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with known hepatocellular carcinoma undergoing MRI of the liver in the UWMC
        Radiology Clinic.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  known hepatocellular carcinoma

          -  undergoing MRI of the liver

        Exclusion Criteria:

          -  Contraindication to MRI with IV contrast
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Orpheus Kolokythas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <reference>
    <citation>Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ. Cancer statistics, 2006. CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30.</citation>
    <PMID>16514137</PMID>
  </reference>
  <reference>
    <citation>Saito K, Kotake F, Ito N, Ozuki T, Mikami R, Abe K, Shimazaki Y. Gd-EOB-DTPA enhanced MRI for hepatocellular carcinoma: quantitative evaluation of tumor enhancement in hepatobiliary phase. Magn Reson Med Sci. 2005;4(1):1-9.</citation>
    <PMID>16127248</PMID>
  </reference>
  <reference>
    <citation>Frericks BB, Loddenkemper C, Huppertz A, Valdeig S, Stroux A, Seja M, Wolf KJ, Albrecht T. Qualitative and quantitative evaluation of hepatocellular carcinoma and cirrhotic liver enhancement using Gd-EOB-DTPA. AJR Am J Roentgenol. 2009 Oct;193(4):1053-60. doi: 10.2214/AJR.08.1946.</citation>
    <PMID>19770329</PMID>
  </reference>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 28, 2010</study_first_submitted>
  <study_first_submitted_qc>October 5, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2010</study_first_posted>
  <last_update_submitted>October 11, 2013</last_update_submitted>
  <last_update_submitted_qc>October 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 14, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HCC</keyword>
  <keyword>hepatocellular carcinoma</keyword>
  <keyword>Eovist</keyword>
  <keyword>MR</keyword>
  <keyword>MRI</keyword>
  <keyword>magnetic resonance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

